EORTC/TROG 01.03 - Glioblastoma/Temozolomide - 26981/22981

By w.paterson
14 August, 2021
0 Comments

Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme. A Randomized Phase III Study

Primary Sponsor

EORTC

Collaborating Groups

TROG Cancer Research

9 January, 2025

Tour de Cure grants support two valuable TROG trials

9 January 2025: Two important TROG Cancer Research trials

7 January, 2025

GenesisCare Foundation $300,000 donation to support TROG work

7 January 2025: TROG Cancer Research is advancing vital

Earlybird registration closes 26 January.

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme. A Randomized Phase III Study

TROG 01.04 – Rectal (Phase III)

EORTC 22996-24002/TROG 01.01 – EPO Head & Neck

Related Post

Tour de Cure grants support two valuable TROG trials

GenesisCare Foundation $300,000 donation to support TROG work

EORTC/TROG 01.03 – Glioblastoma/Temozolomide – 26981/22981

Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme. A Randomized Phase III Study

TROG 01.04 – Rectal (Phase III)

EORTC 22996-24002/TROG 01.01 – EPO Head & Neck

Related Post

Tour de Cure grants support two valuable TROG trials

GenesisCare Foundation $300,000 donation to support TROG work